Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
17.01
-0.20 (-1.16%)
Feb 3, 2026, 2:30 PM EST - Market open

TNXP Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
10.310.097.77---
Revenue Growth (YoY)
-8.79%29.94%----
Cost of Revenue
6.777.774.74---
Gross Profit
3.532.333.03---
Selling, General & Admin
67.5940.134.7530.2223.4714.35
Research & Development
35.8439.9786.6681.8868.8436.16
Operating Expenses
103.4380.07121.41112.0992.3150.51
Operating Income
-99.9-77.74-118.38-112.09-92.31-50.51
Interest & Investment Income
3.65---0.030.05
Other Non Operating Income (Expenses)
-0.886.671.721.87--
EBT Excluding Unusual Items
-97.13-71.08-116.66-110.22-92.29-50.46
Impairment of Goodwill
-0.04-1----
Asset Writedown
0.04-57.96----
Pretax Income
-99.22-130.04-116.66-110.22-92.29-50.46
Net Income
-99.22-130.04-116.66-110.22-92.29-50.46
Preferred Dividends & Other Adjustments
---6.66-1.71
Net Income to Common
-99.22-130.04-116.66-116.88-92.29-52.17
Shares Outstanding (Basic)
61----
Shares Outstanding (Diluted)
61----
EPS (Basic)
-16.22-176.60----
EPS (Diluted)
-16.22-176.60----
Free Cash Flow
-76.32-61.05-109.9-146.2-110.86-57.13
Free Cash Flow Per Share
-12.48-82.90----
Gross Margin
34.31%23.07%38.97%---
Operating Margin
-969.97%-770.20%-1523.94%---
Profit Margin
-963.39%-1288.25%-1501.78%---
Free Cash Flow Margin
-741.06%-604.76%-1414.75%---
EBITDA
-97.46-74.32-114.09-110.84-92.26-50.48
D&A For EBITDA
2.433.424.291.250.050.03
EBIT
-99.9-77.74-118.38-112.09-92.31-50.51
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q